IOncology

The 2026 Pujiang Urologic Oncology Academic Conference was held in Shanghai. In recent years, the rapid development of antibody-drug conjugates (ADCs) and immunotherapy has reshaped the first-line treatment landscape for locally advanced or metastatic urothelial carcinoma (LA/mUC), while closer coordination among systemic therapy, surgery, and long-term follow-up has become increasingly important. Although emerging evidence has provided patients with more treatment options, challenges remain in pretreatment assessment, adverse event management, response evaluation, and long-term follow-up, with the ultimate goal of translating advances from clinical research into sustained real-world benefits. During the conference, Oncology Frontier · UroStream invited Professor Yiping Zhu from Fudan University Shanghai Cancer Center to share his perspectives on first-line treatment innovation, perioperative systemic therapy, the evolving role of surgery, and advances in molecular monitoring.

The rapid development of antibody-drug conjugates (ADCs) and immunotherapy is driving bladder-preservation strategies beyond single-modality local treatment toward an integrated approach combining systemic therapy, local treatment, and molecular stratification. Oncology Frontier – UroStream invited Professor Yijun Shen of Fudan University Shanghai Cancer Center to discuss combination bladder-preservation strategies for high-risk non-muscle-invasive bladder cancer (NMIBC), the implications of perioperative studies in muscle-invasive bladder cancer (MIBC) for traditional treatment pathways, and the potential applications of biomarkers such as circulating tumor DNA (ctDNA) and urinary tumor DNA (utDNA).

The diagnosis and treatment of urological cancers are currently undergoing a period of rapid evolution, driven by simultaneous advances in drug innovation and surgical techniques. Treatment strategies for urothelial carcinoma in the first-line and perioperative settings are evolving rapidly, while surgery for complex renal tumors is shifting from a focus on short-term safety toward greater emphasis on long-term renal function preservation. Against this backdrop, Oncology Frontier · UroStream invited Professor Xin Yao of Tianjin Medical University Cancer Institute and Hospital for an interview. He discussed the evolving treatment landscape of urothelial carcinoma, the priorities of the CACA Urological Oncology Committee, the “five-win” quality-control concept for partial nephrectomy, and future directions for the field.

Systemic therapy for urological tumors is undergoing a profound transformation, shifting from empiric treatment toward mechanism-driven, precision-based risk stratification and whole-course management. In clear cell renal cell carcinoma (ccRCC), the immune-excluded tumor microenvironment is an important factor influencing the efficacy of immune checkpoint inhibitors. In urothelial carcinoma, antibody-drug conjugates (ADCs) combined with immunotherapy are moving beyond first-line treatment for advanced disease and increasingly being explored in the perioperative setting. For von Hippel-Lindau (VHL) syndrome, standardized management of this rare disease and the application of HIF-2α inhibitors are also reshaping traditional approaches to multi-organ intervention. As new mechanisms and therapeutic strategies continue to expand the boundaries of treatment, identifying patients most likely to benefit, dynamically evaluating treatment response, and appropriately transitioning patients with disease progression to subsequent therapies have become key questions in clinical practice. At the 2026 Pujiang Urological Oncology Academic Conference, Oncology Frontier – Urology Frontier invited Professor Hailiang Zhang of Huadong Hospital Affiliated to Fudan University for an exclusive interview. Professor Zhang discussed the mechanisms of immunotherapy resistance in renal cell carcinoma, advances in the diagnosis and treatment of urothelial carcinoma and VHL syndrome, as well as precision treatment selection and whole-course management.

The 2026 Annual Meeting of the Chinese Anti-Cancer Association (CACA) Urological Oncology Committee was held in Tianjin. The meeting brought together experts to discuss standardized diagnosis and treatment of urological cancers, multidisciplinary collaboration, and full-course cancer management. As diagnostic and therapeutic technologies continue to advance, how to truly integrate prevention, screening, diagnosis, treatment, and rehabilitation, while improving long-term patient outcomes through multidisciplinary collaboration, remains an important challenge in clinical practice. During the meeting, Oncology Frontier · UroStream invited Professor Gang Zhu of Beijing United Family Hospital for an interview. He shared his perspectives on the gaps in full-course management of urological cancers, the collaborative model of comprehensive cancer centers, and his vision for the development of the field.

With the accelerating aging of the population, health screening has been increasingly promoted across medical institutions at different levels. As a result, the early detection rates of urologic malignancies, including prostate, bladder, and kidney cancers, have improved, while standardized disease management has received growing attention. Against this backdrop, important challenges in clinical practice include how to achieve more precise diagnosis after a positive prostate cancer screening result while avoiding unnecessary biopsies and overtreatment; how to appropriately balance the clinical benefits of treatment against quality-of-life preservation in older patients; and how to strengthen the capacity of primary healthcare institutions for early detection and standardized initial diagnosis. At the 2026 academic meetings of the Chinese Anti-Cancer Association (CACA) focusing on urologic oncology, Oncology Frontier – UroStream invited Professor Yuanxin Jia from Jixi People's Hospital to share his clinical experience and perspectives on these key issues.

The 2026 Pujiang Urological Oncology Academic Conference was held in Shanghai, bringing together experts from China and abroad to discuss standardized diagnosis and treatment, innovations in surgical techniques, and advances in precision medicine in urological oncology. In recent years, immunotherapy and antibody-drug conjugates (ADCs) have progressively moved from the treatment of advanced urothelial carcinoma (UC) into the perioperative setting, reshaping the overall treatment landscape of bladder cancer. Oncology Frontier – UroStream invited Professor Chunguang Ma of the Department of Urology, Fudan University Shanghai Cancer Center, for an interview to discuss changes in the landscape of adjuvant therapy for UC, the optimal timing and patient selection for adjuvant immunotherapy, future directions for ADC–immunotherapy combinations, and the integration of surgery with systemic therapy, sharing his clinical experience and perspectives on emerging developments.

From July 31 to August 2, 2026, the 2026 “Renyi” Clinical Research Conference on Innovative Anticancer Drugs was held in Nanjing. The conference was part of the academic events celebrating the 90th anniversary of Jiangsu Province Hospital (the First Affiliated Hospital of Nanjing Medical University and Jiangsu Women and Children’s Medical Center). Under the theme “Innovating Drug Development, Driving Translational Research, Celebrating 90 Years of Medical Excellence, and Embarking on a New Journey,” the conference focused on the full development pathway of clinical research on innovative anticancer drugs.

The Northern Breast Cancer Salon was recently held successfully in Qingdao. The meeting focused on the latest advances and clinical hot topics in breast cancer, bringing together numerous experts and scholars for in-depth academic exchange. During the meeting, Professor Wenyan Chen of Nanchang People's Hospital and Professor Ning Xie of Hunan Cancer Hospital respectively shared their perspectives on “Treatment options for HER2-positive metastatic breast cancer after failure of H-based therapy — T-DXd, SHR-A1811, and others.” Following the meeting, Oncology Frontier invited the two professors to further review and elaborate on their respective perspectives, with the aim of providing clinicians with clearer insights and practical guidance on treatment selection after failure of H-based therapy.